NeuShen Pharmaceuticals

NeuShen Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative treatments for central nervous system (CNS) disorders. Founded in 2022 by a team of industry veterans led by Dr. Joan Shen, the company leverages dual technology platforms: an AI-driven small molecule discovery engine and an AAV-based gene therapy platform. Its clinical pipeline is led by NS-041, a KCNQ2/3 activator for epilepsy and depression, and NS-136, an M4 muscarinic receptor positive allosteric modulator for schizophrenia and Alzheimer's-related agitation. With operations in Shanghai and Boston, NeuShen aims to address significant unmet needs in psychiatry and neurology through a global R&D strategy. The company has secured substantial funding from top-tier investors including Lilly Asia Ventures and Lapam Capital.